Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nautilus Biotechnology, Inc.NAUT · Entity 6679 | General Counsel | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nautilus Biotechnology, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2036-03-02 | Direct | 160,000 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 160,000 · Balance 160,000 F1: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 17:31 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001865778-26-000001 · wk-form4_1772663469.xml · derivative · entry 1 Murphy Matthew B. · CIK 0001865778 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2036-03-02 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 18:34 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 20,000 | $0.64 | $12,858.00 |
DisclosureSEC source: 0001865778-25-000003 · wk-form4_1757111657.xml · nonDerivative · entry 1 Murphy Matthew B. · CIK 0001865778 · General Counsel 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 74,140 F1 · ownership.nature: Shares held by the Murphy Family Trust. The reporting person is the Trustee of the Murphy Family Trust. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 16:52 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001808805-25-000026 · wk-form4_1741125162.xml · derivative · entry 1 Murphy Matthew B. · CIK 0001865778 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2035-03-03 F1 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, as defined below, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the Reporting Person remains a Service Provider as provided in the Issuer's 2021 Equity Incentive Plan. Vesting Commencement Date shall mean January 1, 2025. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:34 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001808805-24-000014 · wk-form4_1709674435.xml · derivative · entry 1 Murphy Matthew B. · CIK 0001865778 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2024. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 17:19 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001808805-23-000030 · wf-form4_167770912315422.xml · derivative · entry 1 Murphy Matthew B. · CIK 0001865778 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2023. Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 20:19 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 7,500 | $2.84 | $21,307.50 |
DisclosureSEC source: 0001808805-22-000093 · wf-form4_166069554291105.xml · nonDerivative · entry 2 Murphy Matthew B. · CIK 0001865778 · General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 54,140 F1 · ownership.nature: Shares held by the Murphy Family Trust. The reporting person is the Trustee of the Murphy Family Trust. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 20:19 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 2,500 | $2.85 | $7,125.00 |
DisclosureSEC source: 0001808805-22-000093 · wf-form4_166069554291105.xml · nonDerivative · entry 1 Murphy Matthew B. · CIK 0001865778 · General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 46,640 F1 · ownership.nature: Shares held by the Murphy Family Trust. The reporting person is the Trustee of the Murphy Family Trust. Read SEC document |
| May 12, 2022 Filed May 13, 2022 17:09 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantCommon Stock | 10,000 | $3.28 | $32,800.00 |
DisclosureSEC source: 0001808805-22-000056 · wf-form4_165247602521861.xml · nonDerivative · entry 1 Murphy Matthew B. · CIK 0001865778 · General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 44,140 F1 · ownership.nature: Shares held by the Murphy Family Trust. The reporting person is the Trustee of the Murphy Family Trust. Read SEC document |
| February 25, 2022 Filed Feb 25, 2022 20:10 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001808805-22-000024 · wf-form4_164583778202608.xml · derivative · entry 1 Murphy Matthew B. · CIK 0001865778 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2032-02-25 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is February 25, 2022. Read SEC document |
| August 13, 2021 Filed Aug 13, 2021 21:01 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 5,000 | $7.56 | $37,806.50 |
DisclosureSEC source: 0001808805-21-000010 · wf-form4_162890281874630.xml · nonDerivative · entry 1 Murphy Matthew B. · CIK 0001865778 · General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 34,140 F1 · ownership.direct: Shares held by the Murphy Family Trust. The Reporting Person is the Trustee of the Murphy Family Trust. Read SEC document |
| June 14, 2021 Filed Aug 4, 2021 20:01 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 326,526 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001628280-21-015647 · wf-form4_162812167372819.xml · derivative · entry 1 Murphy Matthew B. · CIK 0001865778 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,526 Underlying: Common Stock · 326,526 shares Expires 2031-06-14 F1 · derivative.exercise_date: Subject to the reporting person continuing to be a Service Provider (as defined in the Company's 2021 Equity Incentive Plan), 25% of the shares subject to such Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date (as defined below), and the balance of the shares subject to such Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary. The Vesting Commencement Date is April 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.